Loading
Some new medicines reprogramme immune cells inside the body with an injection, skipping the factory entirely. Test whether that makes CAR-T affordable and available in ordinary hospitals.
In vivo CAR-T uses targeted lipid nanoparticles or engineered lentiviral vectors to deliver the CAR gene to T cells inside the patient (programmes from Interius, Umoja, Orna, Capstan and others entered the clinic in 2024-25). This idea is not about which antigen to hit but about manufacturing and delivery economics: a frozen vial produced in batches of thousands, administered in a community hospital with no apheresis, no bridging chemotherapy and possibly no lymphodepletion. A companion idea in this corpus covers solid-tumour antigens.
One of the most cited reviews Europe PMC returns for CD19 in Diffuse large B-cell lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for CD19 in Diffuse large B-cell lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One bottleneck page and 22 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One of the most cited reviews Europe PMC returns for CD19 in Diffuse large B-cell lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials, The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19, SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies, Study of Out of Specification for Tisagenlecleucel.
Shares Interius BioTherapeutics, Umoja Biopharma, Orna Therapeutics (Eli Lilly), In vivo CAR-T against solid-tumour antigens.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CD19, Most of the world has almost no cancer care.
Shares ZUMA-1, ZUMA-7, CD19, CAR-T cell therapy.
Shares ZUMA-1, ZUMA-7, Manufacturing cost and time for living and radioactive medicines, CD19.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, Most of the world has almost no cancer care, CAR-T cell therapy.
Shares Talicabtagene autoleucel (NexCAR19) phase 1/2, Manufacturing cost and time for living and radioactive medicines, CD19, Most of the world has almost no cancer care.
Shares ZUMA-1, ZUMA-7, Manufacturing cost and time for living and radioactive medicines, CD19.